Dopaminergic substitution in Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 10, 2002, Pages 1393-1403

  Müller, Thomas ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Dopamine agonists; Fibrosis; Homocysteine; Neuroprotection; Parkinson's disease

Indexed keywords

APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOCRYPTINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; LEVODOPA ETHYLESTER; LISURIDE; MIDODRINE; PERGOLIDE; PIREBEDIL; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; GRANULOMA; HUMAN; HYPOTENSION; INCIDENCE; INJECTION SITE; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PSYCHOSIS; RECEPTOR AFFINITY; REVIEW; RISK FACTOR; SOMNOLENCE; VASCULAR DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; PARKINSON DISEASE; SYNAPTIC TRANSMISSION;

EID: 0036798244     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.10.1393     Document Type: Review

References (122)

1. HOROWSKI R, HOROWSKI L, VOGEL S, POEWE W, KIELHORN FW. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurol (1995) 45(3 Pt 1):565-568.
2. PARKINSON J: An essay of the shaking palsy. London, Sherwood Neely and Jones. (1817).
3. BERNHEIMER H, BIRKMAYER W, HORNYKIEWICZ O, JELLINGER K, SEITELBERGER F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. (1973) 20(4):415-455.
4. FOLEY P. RIEDERER P: Pathogenesis and preclinical course of Parkinson's disease. J. Neural. Transm. Suppl. (1999) 56:31-74.
5. STANWOOD GD, LUCKI I, MCGONIGLE P: Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J. Pharmacol Exp. Ther. (2000) 295(3):1232-1240.
6. SKIRBOLL LR, GRACE AA, BUNNEY BS: Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonist. Science (1979) 206(4414):80-82.
7. DOURISH CT, HERBERT EN, IVERSEN SD: Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ 76. Neuropharmacol (1989) 28(12):1423-1425.
8. KROPF W, KUSCHINSKY K: Electroencephalographic correlates of the sedative effects of dopamine agonist presumably acting on autoreceptors. Neuropharmacol (1991) 30(9):953-960.
9. ANTONINI A, SCHWARZ J, OERTEL WH, POGARELL O, LEENDERS KL: Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and (11C) raclopride. Mov. Disord. (1997) 12(1):33-38.
10. HIRSCH EC: Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann. Neurol. (2000) 47(4 Suppl. 1):Sl15-S120.
11. MILLER JW, SHUKITT-HALE B, VILLALOBOS-MOLINA R, NADEAU MR, SELHUB J, JOSEPH JA: Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol. (1997) 20(1):55-66.
12. HUGHES AJ, LEES AJ, STERN GM: Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurol. (1991) 41(11):1723-1725.
13. AGID Y, AHLSKOG E, ALBANESE A et al.: Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov. Disord (1999) 14(6):911-913.
14. BARBATO L, STOCCHI F, MONGE A et al.: The long-duration action of levodopa may be due to a postsynaptic effect. Clin. Neuropharmacol. (1997) 20(5):394-401.
15. BERRY EM, GROWDON JH, WURTMAN JJ, CABALLERO B, WURTMAN RJ: A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurol. (1991) 41(8):1295-1297.
16. FAHN S: Controversies in the therapy of Parkinson's disease. Adv. Neurol. (1996) 69:477-486.
17. FAHN S: Is levodopa toxic? Neurol (1996) 47(6 Suppl. 3):S 184-S195.
18. DURIF F: Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging (1999) 14(5):337-345.
19. OBESO JA, OLANOW CW, NUTT JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. (2000) 23(10 Suppl.):S2-S7.
20. DESSIBOURG CA, GACHOUD JP: Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson's disease. Schweiz. Rundsch. Med. Prax. (1995) 84(43):1235-1238.
21. DJALDETTI R, INZELBERG R, GILADI N et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov. Disord. (2002) 17(2):297-302.
22. JENNER P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. (2000) 247(Suppl. 2): II43-II50.
23. CHASE TN, OH JD: Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. (2000) 47(4 Suppl. 1): S122-S129.
24. BAAS H, BEISKE AG, GHIKA J et al.: Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry (1997) 63(4):421-428.
25. FACTOR SA, MOLHO ES, FEUSTEL PJ, BROWN DL, EVANS SM: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. (2001) 24(5):295-299.
26. POEWE WH, DEUSCHL G, GORDIN A, KULTALAHTI ER, LEINONEN M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. (2002) 105(4):245-255.
27. MÜLLER T, WOITALLA D, SCHULZ D, PETERS S, KUHNW, PRZUNTEK H: Tolcapone increases maximum concentration of levodopa. J. Neural Transm. (2000) 107(1):113-119.
28. GERLACH M, XIAO AY, KUHN W et al.: The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/ carbidopa treated rats. J. Neural Transm. (2001) 108(2):189-204.
29. MÜLLER T, KUHN W, PRZUNTEK H: Therapy with central active catechol-O-methyltransferase (COMT)- inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. Gen. Sect. (1993) 92(2-3):187-195.
30. RUSS H, MÜLLER T, WOITALLA D, RAHBAR A, HAHN J, KUHN W: Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol (1999) 360(6):719-720.
31. DUPONT E, ANDERSEN A, BOAS J et al.: Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand. (1996) 93(1):14-20.
32. KOLLER WC, HUTTON JT, TOLOSA E, CAPILLDEO R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 53(5):1012-1019.
33. CHASE TN, OH JD, KONITSIOTIS S: Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. (2000) 247(Suppl. 2):II36-II42.
34. VERHAGEN ML, DEL DOTTO P, LEPOOLE K, KONITSIOTIS S, FANG J, CHASE TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56(11):1383-1386.
35. VERHAGEN ML, DEL DOTTO P, VAN DEN MP, FANG J, MOURADIAN MM, CHASE TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurol. (1998) 50(5):1323-1326.
36. RASCOL O: The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J. Neurol. (2000) 247(Suppl. 2):II51-II57.
37. MERIMS D, ZIV I, DJALDETTI R, MELAMED E: Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet (1999) 353(9166):1764-1765.
38. SPIEKER S, LOSCHMANN PA, KLOCKGETHER T: The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov. Disord. (1999) 14(3):517-519.
39. BIBBIANI F, OH JD, CHASE TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurol. (2001) 57(10):1829-1834.
40. AGID Y. Levodopa: is toxicity a myth? Neurol. (1998) 50(4):858-863.
41. MURER MG, DZIEWCZAPOLSKI G, MENALLED LB et al.: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. (1998) 43(5):561-575.
42. BEN SHLOMO Y, MARMOT MG: Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J. Neurol. Neurosurg. Psychiatry (1995) 58(3):293-299.
43. GORELL JM, JOHNSON CC, RYBICKI BA: Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurol. (1994) 44(10):1865-1868.
44. ALLAIN P, LE BOUIL A, CORDILLET E, LE QUAY L, BAGHERI H, MONTASTRUC JL: Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicol. (1995) 16(3):527-529.
45. KUHN W, ROEBROEK R, BLOM H, VAN OPPENRAAIJ D, MÜLLER T: Hyperhomocysteinaemia in Parkinson's disease. J. Neurol. (1998) 245(12):811-812.
46. KUHN W, ROEBROEK R, BLOM H et al.: Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. (1998) 40(4):225-227.
47. BLANDINI F, FANCELLU R, MARTIGNONI E et al.: Plasma homocysteine and 1-dopa metabolism in patients with Parkinson's disease. Clin. Chem. (2001) 47(6):1102-1104.
48. KUHN W, HUMMEL T, WOITALLA D, MÜLLER T: Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurol. (2001) 56(2):281-282.
49. MÜLLER T, WOITALLA D, HAUPTMANN B, FOWLER B, KUHN W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. (2001) 308(1):54-56.
50. YASUI K, KOWA H, NAKASO K, TAKESHIMA T, NAKASHIMA K: Plasma homocysteine and MTHFR C677F genotype in levodopa-treated patients with PD. Neurol. (2000) 55(3):437-440.
51. MÜLLER T, WERNE B, FOWLER B, KUHN W: Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet (1999) 354(9173):126-127.
52. MÜLLER T, WOITALLA D, FOWLER B, KUHN W: 3-OMD and homocysteine plasma levels in parkinsonian patients. J. Neural Transm. (2002) 109(2):175-179.
53. CHAMBERS JC, MCGREGOR A, JEAN-MARIE J, KOONER JS: Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet (1998) 351(9095):36-37.
54. PERRY IJ: Homocysteine and risk of stroke. J. Cardiovasc. Risk (1999) 6(4):235-240.
55. SCHLUSSEL E, PREIBISCH G, PUTTER S, ELSTNER EF: Homocysteine-induced oxidative damage: mechanisms and possible roles in neurodegenerative and atherogenic processes. Z. Naturforsch (C.) (1995) 50(9-10): 699-707.
56. MÜLLER T. Non-dopaminergic drug treatment of Parkinson's disease. Expert. Opin. Pharmacother. (2001) 2(4):557-572.
57. BEAL MF: Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. (1998) 44(3 Suppl. 1):S110-S114.
58. GERLACH M, BLUM-DEGEN D, LAN J, RIEDERER P: Nitric oxide in the pathogenesis of Parkinson's disease. Adv. Neurol. (1999) 80:239-245.
59. LIPTON SA, KIM WK, CHOI YB et al.: Neurotoxicity associated with dual actions of homocysteine at the N- methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA (1997) 94(11):5923-5928.
60. KANG SS, WONG PW: Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis (1996) 119(2):135-138.
61. SACHDEV PS, VALENZUELA M, WANG XL, LOOI JC, BRODATY H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurol (2002) 58(10):1539-1541.
62. MALINOW MR. Homocyst(e)ine, vitamins and genetic interactions in vascular disease. Can. J. Cardiol. (1999) 15(Suppl.B): 31B-34B.
63. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol. (2000) 23(1):34-44.
64. HELY MA, MORRIS JG, TRAFICANTE R, REID WG, O'SULLIVAN DJ, WILLIAMSON PM: The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry (1999) 67(3):300-307.
65. PRZUNTEK H, WELZEL D, GERLACH M et al.: Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm. Gen. Sect. (1996) 103(6):699-715.
66. RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
67. RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs (1998) 55(Suppl. 1): 23-30.
68. RINNE UK: Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy. Nervenarzt (1999) 70(Suppl. 1):S19-S25.
69. MAREK K, SEIBYL J, SHOULSON I et al.: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson's disease progression. JAMA (2002) 287(13):1653-1661.
70. COLOSIMO C, MERELLO M, HUGHES AJ, SIERADZAN K, LEES AJ: Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J. Neurol. Neurosurg. Psychiatry (1996) 60(6):634-637.
71. GOETZ CG, DIEDERICH NJ: Dopaminergic agonist in the treatment of Parkinson's disease. Neurol. Clin. (1992) 10(2):527-540.
72. HUGHES AJ, LEES AJ, STERN GM: Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin. Neuropharmacol. (1990) 13(4):312-317.
73. LEES AJ: Dopamine agonist in Parkinson's disease: a look at apomorphine. Fundam. Clin. Pharmacol. (1993) 7(3-4):121-128.
74. MERELLO M, PIKIELNY R, CAMMAROTA A, LEIGUARDA R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-close study. Clin. Neurophamacol. (1997) 20(2):165-167.
75. MONTASTRUC JL, RASCOL O, SENARD JM: Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. (1991) 14(5):432-437.
76. CALNE DB: Early idiopathic parkinsonism: initiation and optimization of treatment. Clin. Neuropharmacol. (1994) 17(Suppl. 2):S14-S18.
77. NAKANISHI T, MIZUNO Y, GOTO I et al.: A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Eur. Neurol. (1991) 31(Suppl. 1):3-16.
78. PRZUNTEK H, WELZEL D, BLUMNER E et al.: Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued (see comments). Eur. J. Clin. Pharmacol. (1992) 43(4):357-363.
79. BAAS HK, SCHUELER P: Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur. Neurol (2001) 46(Suppl. 1):18-23.
80. CLARKE CE, DEANE KD: Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. (2001) (1):CD001519.
81. COLAO A, LOMBARDI G, ANNUNZIATO L: Cabergoline. Expert. Opin. Pharmacother. (2000) 1(3):555-574.
82. ALLAIN H, DESTEE A, PETIT H et al.: Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur. Neurol (2000) 44(1):22-30.
83. CLARKE CE, SPELLER JM: Lisuride for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. (2000) (2):CD001515.
84. GILLE G, RAUSCH WD, HUNG ST et al.: Protection of dopaminergic neurons in primary culture by lisuride. J. Neural Transm. (2002) 109(2):157-169.
85. JANSEN PA, HERINGS RM, SAMSON MM et al.: Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin. Neuropharmacol. (2001) 24(3):177-180.
86. BONUCCELLI U, COLZI A, DEL DOTTO P: Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin. Neuropharmacol (2002) 25(1):1-10.
87. DELEU D, NORTHWAY MG, HANSSENS Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. (2002) 41(4):261-309.
88. HUBBLE JP: Long-term studies of dopamine agonist. Neurol (2002) 58(4 Suppl. 1):S42-S50.
89. KAYE CM, NICHOLLS B: Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. (2000) 39(4):243-254.
90. GIMENEZ-ROLDAN S, ESTEBAN EM, MATEO D: Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin. Neuropharmacol (2001) 24(6):346-351.
91. BRUNT ER, BROOKS DJ, KORCZYN AD, MONTASTRUC JL, STOCCHI F: A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.J. Neural Transm. (2002) 109(4):489-502.
92. HOMANN CN, WENZEL K, SUPPAN K et al.: Sleep attacks in patients taking dopamine agonist: review. Br. Med. J. (2002) 324(7352):1483-1487.
93. SCHRAG A, KEENS J, WARNER J: Ropinirole for the treatment of tremor in early Parkinson's disease. Eur. J. Neurol. (2002) 9(3):253-257.
94. BIGLAN KM, HOLLOWAY RG: A review of pramipexole and its clinical utility in Parkinson's disease. Expert. Opin. Pharmacother. (2002) 3(2):197-210.
95. POGARELL O, GASSER T, VAN HILTEN JJ et al.: Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind: placebo controlled multicentre study. J. Neurol. Neurosurg. Psychiatry (2002) 72(6):713-720.
96. GOETZ CG, BLASUCCI L, STEBBINS GT: Switching dopamine agonist in advanced Parkinson's disease: is rapid titration preferable to slow? Neurol. (1999) 52(6):1227-1229.
97. GOETZ CG, TANNER CM, GLANTZ RH, KLAWANS HL: Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurol. (1985) 35(5):749-751.
98. GOETZ CG, SHANNON KM, TANNER CM, CARROLL VS, KLAWANS HL: Agonist substitution in advanced Parkinson's disease. Neurol. (1989) 39(8):1121-1122.
99. HUTTON JT, METMAN LV, CHASE TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. (2001) 16(3):459-463.
100. LEWITT PA: Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and α-tocopherol treatment. J. Neural Transm. Suppl. (1994) 43:171-181.
101. PRZUNTEK H, CONRAD B, DICHGANS J et al.: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur. J. Neurol. (1999) 6(2):141-150.
102. TOGGAS SM, MASLIAH E, MUCKE L: Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. (1996) 706(2):303-307.
103. BURSTEIN ME, SERBIN AV, KHAKHULINA TV et al.: Inhibition of HIV-1 replication by newly developed adamantane- containing polyanionic agents. Antiviral Res. (1999) 41(3):135-144.
104. NATH A, HAUGHEY NJ, JONES M, ANDERSON C, BELL JE, GEIGER JD: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. (2000) 47(2):186-194.
105. UITTI RJ, RAJPUT AH, AHLSKOG JE et al.: Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurol. (1996) 46(6):1551-1556.
106. OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurol. (1998) 51(3):825-830.
107. DEIGNER HP, HABERKORN U, KINSCHERF R: Apoptosis modulators in the therapy of neurodegenerative diseases. Expert. Opin. Investig. Drugs (2000) 9(4):747-764.
108. HIRSCH EC, HUNOT S, FAUCHEUX B, et al.: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. (1999) 14(2):383-385.
109. OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosci. (1999) 22:123-144.
110. INNIS RB, MAREK KL, SHEFF K et al.: Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with (123I)β-CIT. Mov. Disord. (1999) 14(3):436-442.
111. SEIBYL JP, MAREK K, SHEFF K et al.: Test/retest reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J. Nucl. Med. (1997) 38(9):1453-1459.
112. AHLSKOG JE, UITTI RJ, O'CONNOR MK et al.: The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov. Disord (1999) 14(6):940-946.
113. EKESBO A, RYDIN E, TORSTENSON R, SYDOW O, LAENGSTROM B, TEDROFF J: Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurol. (1999) 52(1):120-125.
114. BLUM-DEGEN D, MÜLLER T, KUHN W, GERLACH M, PRZUNTEK H, RIEDERER P: Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. (1995) 202(1-2):17-20.
115. MOGI M, HARADA M, NARABAYASHI H, INAGAKI H, MINAMI M, NAGATSU T: Interleukin (IL)-1 β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. (1996) 211(1):13-16.
116. MCGEER PL, MCGEER EG: Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord (1998) 12(Suppl. 2):S1-S6.
117. MOGI M, NAGATSU T. Neurotrophins and cytokines in Parkinson's disease. Adv. Neurol. (1999) 80:135-139.
118. MASTRONARDI CA, YU WH, MCCANN S: Lipopolysaccharide-induced tumor necrosis factor-α release is controlled by the central nervous system. Neuroimmunomodulation (2001) 9(3):148-156.
119. SHAUNAK S, WILKINS A, PILLING JB, DICK DJ: Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J. Neurol. Neurosurg. Psychiatry (1999) 66(1):79-81.
120. IVERSEN BM, JOHANNESEN JW, NORDAHL E, OFSTAD J, THUNOLD S, WILLASSEN Y. Retroperitoneal fibrosis during treatment with methydopa. Lancet (1975) 2(7929):302-304.
121. CLARKE CE: Medical management of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (2002) 72(Suppl. 1):I22-I27.
122. PRZUNTEK H, BITTKAU S, BLIESATH H et al.: Budipine provides additional benefit in patients with Parkinson's disease receiving a stable optimum dopaminergic drug regimen. Arch. Neurol. (2002) 59(5):803-806.